Exploring benzothiazole derivatives: Promising PLK1 Inhibitors for cancer therapy through Virtual screening, Molecular docking, and ADMET evaluation

Simple item page
dc.contributor.authorPatel, Shivkanten_US
dc.contributor.authorShah, Ashishen_US
dc.contributor.authorSen, Ashim Kumaren_US
dc.date.accessioned2025-08-13T11:17:16Z
dc.date.available2025-08-13T11:17:16Z
dc.date.issued2025-06
dc.description.abstractThe search for effective cancer therapies has driven significant interest in targeting Polo-like kinase 1 (PLK1), a crucial regulator of cell cycle progression, mitosis, epithelial-mesenchymal transition, autophagy, and DNA replication. Over expression of PLK1 is frequently observed in various cancers, making it a promising therapeutic target. Given the need for novel and potent PLK1 inhibitors, this study investigates the benzothiazole-containing drug 5f-203, known for inducing cell cycle arrest, as a potential PLK1 inhibitor. Using the PubChem database, novel PLK1 inhibitors were identified with 5f-203 (clinical trial, Phase 1) as the reference molecule. A comprehensive computational approach, including virtual screening, ligand and protein preparation, grid building, and molecular docking, was employed to evaluate co-crystallized ligand 5f-203, screened molecules, and newly designed compounds (N1-N6). Protein validation using ProSA (-7.9), ERRAT (95.36%), and the Ramachandran plot (84.1% residues in favored regions) confirmed model reliability. Lipinski’s rule was applied as an additional filter, and molecular docking revealed binding affinity values ranging from -8.82 to -7.73 kcal/mol, with molecule P1 exhibiting the highest affinity (-8.82 kcal/mol). Interaction analysis showed that 5f-203 formed H-bonds with Arg120 and NH2, while Ala66, Arg122, and Ile118 contributed to pi-alkyl interactions. Newly designed compounds (N1-N6) outperformed 5f-203 in docking scores, with synthetic accessibility below 4.5. ADMET studies further supported their drug-like potential. These findings suggest that the top 10 screened hits and newly designed benzothiazole derivatives hold promise as PLK1 inhibitors, offering a potential avenue for cancer therapy.en_US
dc.identifier.affiliationsDepartment of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara-391 760, Gujarat, Indiaen_US
dc.identifier.affiliationsDepartment of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara-391 760, Gujarat, Indiaen_US
dc.identifier.affiliationsDepartment of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara-391 760, Gujarat, Indiaen_US
dc.identifier.citationPatel Shivkant, Shah Ashish, Sen Ashim Kumar . Exploring benzothiazole derivatives: Promising PLK1 Inhibitors for cancer therapy through Virtual screening, Molecular docking, and ADMET evaluation . Indian Journal of Biochemistry & Biophysics. 2025 Jun; 62(6): 584-595en_US
dc.identifier.issn0301-1208
dc.identifier.issn0975-0959
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/253478
dc.languageenen_US
dc.publisherCSIR-National Institute of Science Communication and Policy Research (NIScPR)en_US
dc.relation.issuenumber6en_US
dc.relation.volume62en_US
dc.source.urihttps://doi.org/10.56042/ijbb.v62i6.9056en_US
dc.subject5f-203en_US
dc.subjectAdsorptionen_US
dc.subjectAnti-cancer agentsen_US
dc.subjectBenzothiazoleen_US
dc.subjectDistributionen_US
dc.subjectDockingen_US
dc.subjectExcretionen_US
dc.subjectLipinski ruleen_US
dc.subjectMetabolismen_US
dc.subjectPolo like kinase1 (PLK1)en_US
dc.titleExploring benzothiazole derivatives: Promising PLK1 Inhibitors for cancer therapy through Virtual screening, Molecular docking, and ADMET evaluationen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ijbb2025v62n6p584.pdf
Size:
2.29 MB
Format:
Adobe Portable Document Format
Download
Collections
Indian Journal of Biochemistry & Biophysics